nodes	percent_of_prediction	percent_of_DWPC	metapath
Rizatriptan—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.0689	0.083	CbGpPWpGaD
Rizatriptan—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.0547	0.0658	CbGpPWpGaD
Rizatriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0315	0.0379	CbGpPWpGaD
Rizatriptan—HTR1F—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0279	0.0336	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.023	0.0277	CbGpPWpGaD
Rizatriptan—HTR1F—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0196	0.0236	CbGpPWpGaD
Rizatriptan—HTR1F—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.019	0.0229	CbGpPWpGaD
Rizatriptan—HTR1F—nervous system—Gilles de la Tourette syndrome	0.0182	0.119	CbGeAlD
Rizatriptan—HTR1D—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0178	0.0215	CbGpPWpGaD
Rizatriptan—HTR1F—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0177	0.0213	CbGpPWpGaD
Rizatriptan—HTR1F—central nervous system—Gilles de la Tourette syndrome	0.0175	0.115	CbGeAlD
Rizatriptan—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0175	0.021	CbGpPWpGaD
Rizatriptan—Sumatriptan—DRD2—Gilles de la Tourette syndrome	0.0165	1	CrCbGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0165	0.0198	CbGpPWpGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.016	0.0193	CbGpPWpGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0149	0.0179	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0147	0.0177	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0144	0.0173	CbGpPWpGaD
Rizatriptan—HTR1F—brain—Gilles de la Tourette syndrome	0.0139	0.091	CbGeAlD
Rizatriptan—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0133	0.016	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0125	0.0151	CbGpPWpGaD
Rizatriptan—HTR1F—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0124	0.0149	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0123	0.0148	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0122	0.0147	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0119	0.0143	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0113	0.0136	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0111	0.0134	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.011	0.0132	CbGpPWpGaD
Rizatriptan—HTR1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0105	0.0127	CbGpPWpGaD
Rizatriptan—HTR1F—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0104	0.0126	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0103	0.0124	CbGpPWpGaD
Rizatriptan—HTR1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0102	0.0123	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.01	0.0121	CbGpPWpGaD
Rizatriptan—HTR1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00953	0.0115	CbGpPWpGaD
Rizatriptan—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00935	0.0113	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00933	0.0112	CbGpPWpGaD
Rizatriptan—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00908	0.0109	CbGpPWpGaD
Rizatriptan—HTR1B—midbrain—Gilles de la Tourette syndrome	0.00907	0.0593	CbGeAlD
Rizatriptan—HTR1D—midbrain—Gilles de la Tourette syndrome	0.00879	0.0574	CbGeAlD
Rizatriptan—HTR1F—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00871	0.0105	CbGpPWpGaD
Rizatriptan—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00846	0.0102	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00845	0.0102	CbGpPWpGaD
Rizatriptan—HTR1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00794	0.00956	CbGpPWpGaD
Rizatriptan—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00786	0.00946	CbGpPWpGaD
Rizatriptan—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00777	0.00936	CbGpPWpGaD
Rizatriptan—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00763	0.00919	CbGpPWpGaD
Rizatriptan—HTR1B—nervous system—Gilles de la Tourette syndrome	0.00746	0.0488	CbGeAlD
Rizatriptan—HTR1A—midbrain—Gilles de la Tourette syndrome	0.00732	0.0479	CbGeAlD
Rizatriptan—HTR1D—nervous system—Gilles de la Tourette syndrome	0.00722	0.0472	CbGeAlD
Rizatriptan—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00718	0.0469	CbGeAlD
Rizatriptan—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00711	0.00856	CbGpPWpGaD
Rizatriptan—HTR1D—central nervous system—Gilles de la Tourette syndrome	0.00695	0.0455	CbGeAlD
Rizatriptan—MAOA—midbrain—Gilles de la Tourette syndrome	0.00669	0.0437	CbGeAlD
Rizatriptan—HTR1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00667	0.00804	CbGpPWpGaD
Rizatriptan—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00654	0.00787	CbGpPWpGaD
Rizatriptan—HTR1A—nervous system—Gilles de la Tourette syndrome	0.00602	0.0394	CbGeAlD
Rizatriptan—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00592	0.00713	CbGpPWpGaD
Rizatriptan—HTR1A—central nervous system—Gilles de la Tourette syndrome	0.0058	0.0379	CbGeAlD
Rizatriptan—HTR1B—brain—Gilles de la Tourette syndrome	0.0057	0.0373	CbGeAlD
Rizatriptan—HTR1D—brain—Gilles de la Tourette syndrome	0.00552	0.0361	CbGeAlD
Rizatriptan—HTR1F—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00552	0.00664	CbGpPWpGaD
Rizatriptan—MAOA—nervous system—Gilles de la Tourette syndrome	0.0055	0.0359	CbGeAlD
Rizatriptan—MAOA—central nervous system—Gilles de la Tourette syndrome	0.00529	0.0346	CbGeAlD
Rizatriptan—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00498	0.00599	CbGpPWpGaD
Rizatriptan—HTR1A—brain—Gilles de la Tourette syndrome	0.0046	0.0301	CbGeAlD
Rizatriptan—MAOA—brain—Gilles de la Tourette syndrome	0.0042	0.0275	CbGeAlD
Rizatriptan—HTR1F—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00408	0.00491	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00396	0.00476	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00378	0.00455	CbGpPWpGaD
Rizatriptan—HTR1F—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00369	0.00444	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00367	0.00442	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00342	0.00412	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00324	0.0039	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00315	0.00379	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00293	0.00353	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00261	0.00314	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00255	0.00307	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00253	0.00305	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00248	0.00298	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00247	0.00297	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00242	0.00291	CbGpPWpGaD
Rizatriptan—HTR1F—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0024	0.00288	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0024	0.00288	CbGpPWpGaD
Rizatriptan—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00239	0.00288	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00237	0.00285	CbGpPWpGaD
Rizatriptan—HTR1D—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00236	0.00284	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00235	0.00283	CbGpPWpGaD
Rizatriptan—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00231	0.00278	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0023	0.00277	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00223	0.00269	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00219	0.00263	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00214	0.00258	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00207	0.0025	CbGpPWpGaD
Rizatriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00205	0.00247	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00203	0.00244	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00201	0.00242	CbGpPWpGaD
Rizatriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00201	0.00242	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00197	0.00237	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00194	0.00234	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00189	0.00227	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00187	0.00226	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00184	0.00221	CbGpPWpGaD
Rizatriptan—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00183	0.00221	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.0018	0.00217	CbGpPWpGaD
Rizatriptan—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00176	0.00212	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00175	0.00211	CbGpPWpGaD
Rizatriptan—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00171	0.00206	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00163	0.00196	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00158	0.0019	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00156	0.00188	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00155	0.00186	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00155	0.00186	CbGpPWpGaD
Rizatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00153	0.00184	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00153	0.00184	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0015	0.00181	CbGpPWpGaD
Rizatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00181	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0015	0.00181	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00143	0.00172	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0014	0.00168	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0014	0.00168	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00139	0.00168	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00135	0.00163	CbGpPWpGaD
Rizatriptan—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.00133	0.0016	CbGpPWpGaD
Rizatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00131	0.00158	CbGpPWpGaD
Rizatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00129	0.00155	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00127	0.00153	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00126	0.00152	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00123	0.00148	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00118	0.00142	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00115	0.00138	CbGpPWpGaD
Rizatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00114	0.00138	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00114	0.00138	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00106	0.00128	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.001	0.0012	CbGpPWpGaD
Rizatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000979	0.00118	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000979	0.00118	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000892	0.00107	CbGpPWpGaD
Rizatriptan—HTR1F—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000883	0.00106	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000873	0.00105	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000866	0.00104	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000848	0.00102	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00081	0.000975	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000807	0.000971	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000802	0.000966	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000793	0.000955	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00079	0.000951	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000786	0.000947	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00077	0.000927	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000748	0.000901	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000746	0.000898	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000732	0.000882	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000726	0.000875	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000717	0.000864	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000677	0.000815	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000665	0.000801	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000646	0.000778	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000604	0.000727	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000602	0.000724	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000586	0.000706	CbGpPWpGaD
Rizatriptan—HTR1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000565	0.00068	CbGpPWpGaD
Rizatriptan—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000553	0.000666	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000546	0.000658	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000513	0.000618	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000502	0.000605	CbGpPWpGaD
Rizatriptan—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.00049	0.00059	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000478	0.000576	CbGpPWpGaD
Rizatriptan—HTR1F—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000474	0.000571	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000468	0.000564	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000464	0.000559	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000455	0.000548	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000433	0.000521	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000424	0.00051	CbGpPWpGaD
Rizatriptan—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000421	0.000507	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000383	0.000461	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000357	0.00043	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000346	0.000417	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000323	0.000389	CbGpPWpGaD
Rizatriptan—HTR1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000303	0.000365	CbGpPWpGaD
Rizatriptan—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000297	0.000357	CbGpPWpGaD
Rizatriptan—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000226	0.000272	CbGpPWpGaD
